Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.

Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, McAvoy C, Lacombe V, Ardois S, Campochiaro C, Maria A, Coustal C, Comont T, Lazaro E, Lifermann F, Le Guenno G, Lobbes H, Grobost V, Outh R, Campagne J, Dor-Etienne A, Garnier A, Jamilloux Y, Dossier A, Samson M, Audia S, Nicolas B, Mathian A, de Maleprade B, De Sainte-Marie B, Faucher B, Bouaziz JD, Broner J, Dumain C, Antoine C, Carpentier B, Castel B, Lartigau-Roussin C, Crickx E, Volle G, Fayard D, Decker P, Moulinet T, Dumont A, Nguyen A, Aouba A, Martellosio JP, Levavasseur M, Puigrenier S, Antoine P, Giraud JT, Hermine O, Lacout C, Martis N, Karam JD, Chasset F, Arnaud L, Marianetti P, Deligny C, Chazal T, Woaye-Hune P, Roux-Sauvat M, Meyer A, Sujobert P, Hirsch P, Abisror N, Fenaux P, Kosmider O, Jachiet V, Fain O, Terrier B, Mekinian A, Georgin-Lavialle S, FRENVEX

Open source

DOI
10.1136/ard-2024-225640
Published
2024 Sep 30
Container
Annals of the rheumatic diseases
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/ard-2024-225640,
  title = {Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.},
  author = {Hadjadj J and Nguyen Y and Mouloudj D and Bourguiba R and Heiblig M and Aloui H and McAvoy C and Lacombe V and Ardois S and Campochiaro C and Maria A and Coustal C and Comont T and Lazaro E and Lifermann F and Le Guenno G and Lobbes H and Grobost V and Outh R and Campagne J and Dor-Etienne A and Garnier A and Jamilloux Y and Dossier A and Samson M and Audia S and Nicolas B and Mathian A and de Maleprade B and De Sainte-Marie B and Faucher B and Bouaziz JD and Broner J and Dumain C and Antoine C and Carpentier B and Castel B and Lartigau-Roussin C and Crickx E and Volle G and Fayard D and Decker P and Moulinet T and Dumont A and Nguyen A and Aouba A and Martellosio JP and Levavasseur M and Puigrenier S and Antoine P and Giraud JT and Hermine O and Lacout C and Martis N and Karam JD and Chasset F and Arnaud L and Marianetti P and Deligny C and Chazal T and Woaye-Hune P and Roux-Sauvat M and Meyer A and Sujobert P and Hirsch P and Abisror N and Fenaux P and Kosmider O and Jachiet V and Fain O and Terrier B and Mekinian A and Georgin-Lavialle S and FRENVEX},
  year = {2024},
  journal = {Annals of the rheumatic diseases},
  doi = {10.1136/ard-2024-225640},
  url = {https://doi.org/10.1136/ard-2024-225640}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
AU  - Hadjadj J
AU  - Nguyen Y
AU  - Mouloudj D
AU  - Bourguiba R
AU  - Heiblig M
AU  - Aloui H
AU  - McAvoy C
AU  - Lacombe V
AU  - Ardois S
AU  - Campochiaro C
AU  - Maria A
AU  - Coustal C
AU  - Comont T
AU  - Lazaro E
AU  - Lifermann F
AU  - Le Guenno G
AU  - Lobbes H
AU  - Grobost V
AU  - Outh R
AU  - Campagne J
AU  - Dor-Etienne A
AU  - Garnier A
AU  - Jamilloux Y
AU  - Dossier A
AU  - Samson M
AU  - Audia S
AU  - Nicolas B
AU  - Mathian A
AU  - de Maleprade B
AU  - De Sainte-Marie B
AU  - Faucher B
AU  - Bouaziz JD
AU  - Broner J
AU  - Dumain C
AU  - Antoine C
AU  - Carpentier B
AU  - Castel B
AU  - Lartigau-Roussin C
AU  - Crickx E
AU  - Volle G
AU  - Fayard D
AU  - Decker P
AU  - Moulinet T
AU  - Dumont A
AU  - Nguyen A
AU  - Aouba A
AU  - Martellosio JP
AU  - Levavasseur M
AU  - Puigrenier S
AU  - Antoine P
AU  - Giraud JT
AU  - Hermine O
AU  - Lacout C
AU  - Martis N
AU  - Karam JD
AU  - Chasset F
AU  - Arnaud L
AU  - Marianetti P
AU  - Deligny C
AU  - Chazal T
AU  - Woaye-Hune P
AU  - Roux-Sauvat M
AU  - Meyer A
AU  - Sujobert P
AU  - Hirsch P
AU  - Abisror N
AU  - Fenaux P
AU  - Kosmider O
AU  - Jachiet V
AU  - Fain O
AU  - Terrier B
AU  - Mekinian A
AU  - Georgin-Lavialle S
AU  - FRENVEX
PY  - 2024
JO  - Annals of the rheumatic diseases
DO  - 10.1136/ard-2024-225640
UR  - https://doi.org/10.1136/ard-2024-225640
ER  - 

APA

J, H., Y, N., D, M., R, B., M, H., H, A., C, M., V, L., S, A., C, C., A, M., C, C., T, C., E, L., F, L., G, L. G., H, L., V, G., R, O., J, C., A, D., A, G., Y, J., A, D., M, S., S, A., B, N., A, M., B, D. M., B, D. S., B, F., JD, B., J, B., C, D., C, A., B, C., B, C., C, L., E, C., G, V., D, F., P, D., T, M., A, D., A, N., A, A., JP, M., M, L., S, P., P, A., JT, G., O, H., C, L., N, M., JD, K., F, C., L, A., P, M., C, D., T, C., P, W., M, R., A, M., P, S., P, H., N, A., P, F., O, K., V, J., O, F., B, T., A, M., S, G., & FRENVEX (2024). Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.. Annals of the rheumatic diseases. https://doi.org/10.1136/ard-2024-225640

Source records